Chrysin loaded Nanostructured lipid carrier (NLC) drug delivery system: Harnessing neuroprotective effects in the management of Alzheimer’s Disease

Khandale, NB; Birla, DS; Bashir, B; Singh, SK; Vishwas, S; Gulati, M; Dua, K

Chrysin loaded Nanostructured lipid carrier (NLC) drug delivery system: Harnessing neuroprotective effects in the management of Alzheimer’s Disease

Khandale, NB Birla, DS Bashir, B Singh, SK Vishwas, S Gulati, M Dua, K

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Alzheimer's & Dementia, 2024, 20, (Suppl 6), pp. e088755
Issue Date:: 2024-12

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (70.09 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Khandale, NB
dc.contributor.author	Birla, DS
dc.contributor.author	Bashir, B
dc.contributor.author	Singh, SK
dc.contributor.author	Vishwas, S
dc.contributor.author	Gulati, M
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2025-03-31T03:28:41Z
dc.date.available	2025-03-31T03:28:41Z
dc.date.issued	2024-12
dc.identifier.citation	Alzheimer's & Dementia, 2024, 20, (Suppl 6), pp. e088755
dc.identifier.issn	1552-5260
dc.identifier.issn	1552-5279
dc.identifier.uri	http://hdl.handle.net/10453/186344
dc.description.abstract	<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Alzheimer’s Disease (AD) poses a substantial global health burden, necessitating innovative therapeutic strategies. This study investigates the neuroprotective potential of a chrysin‐loaded Nanostructured Lipid Carrier (NLC) drug delivery system in AD management. Employing the high‐pressure homogenization method, chrysin‐loaded NLCs were meticulously formulated to optimize drug delivery efficiency. The research explores the multifaceted neuroprotective effects of chrysin, a naturally occurring flavonoid, within the context of AD pathology. The intricate mechanisms of action underlying the chrysin‐loaded NLCs are elucidated, shedding light on their potential to modulate key pathways implicated in AD progression. This study advances our understanding of tailored drug delivery systems, specifically highlighting the therapeutic promise of chrysin‐loaded NLCs for the nuanced management of Alzheimer’s Disease.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>To overcome these challenges, a Nanostructured lipid carrier (NLC) for Chrysin was devised, employing quality by design (QbD) based Box‐Behnken design (BBD). NLC offers numerous advantages, encompassing increased drug loading, facile preparation, exceptional stability, as well as enhanced bioavailability and permeability across the blood‐brain barrier.</jats:p></jats:sec><jats:sec><jats:title>Result</jats:title><jats:p>The optimized Chrysin‐loaded NLC formulation exhibited Particle Size, PDI, zeta potential, and drug loading as 66.45nm, 0.19, ‐22mV, and 98% respectively. The formulation was found to be stable after six months in accelerated stability studies. The formulation underwent various pharmacodynamic studies. Pharmacodynamic studies assessed cognitive and motor functions in rats, revealing significant improvements in cognition with both low and high doses respectively. Additionally, the biochemical investigations revealed that the Chrysin‐loaded NLCs effectively decreased the levels AChE enzyme, amyloid β, oxidative stress, and neuroinflammation.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This study explores Chrysin‐loaded NLCs as a solution for challenges in Alzheimer’s Disease (AD) treatment. The optimized formulation overcomes Chrysin’s solubility issues, demonstrating improved bioavailability and permeability. Chrysin‐loaded NLCs hold promise as a neuroprotective for AD.</jats:p></jats:sec>
dc.language	en
dc.publisher	Wiley
dc.relation.ispartof	Alzheimer's & Dementia
dc.relation.isbasedon	10.1002/alz.088755
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1103 Clinical Sciences, 1109 Neurosciences
dc.subject.classification	Geriatrics
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	3209 Neurosciences
dc.subject.classification	5202 Biological psychology
dc.title	Chrysin loaded Nanostructured lipid carrier (NLC) drug delivery system: Harnessing neuroprotective effects in the management of Alzheimer’s Disease
dc.type	Journal Article
utslib.citation.volume	20
utslib.for	1103 Clinical Sciences
utslib.for	1109 Neurosciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)/Centre for Inflammation (CFI) Associate Members
pubs.organisational-group	University of Technology Sydney/UTS Groups/Australian Research Consortium in Complementary and Integrative Medicine (ARCCIM)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Stroke Research Collaborative
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2025-03-31T03:28:38Z
pubs.issue	Suppl 6
pubs.publication-status	Published
pubs.volume	20
utslib.citation.issue	Suppl 6

Abstract:

AbstractBackgroundAlzheimer’s Disease (AD) poses a substantial global health burden, necessitating innovative therapeutic strategies. This study investigates the neuroprotective potential of a chrysin‐loaded Nanostructured Lipid Carrier (NLC) drug delivery system in AD management. Employing the high‐pressure homogenization method, chrysin‐loaded NLCs were meticulously formulated to optimize drug delivery efficiency. The research explores the multifaceted neuroprotective effects of chrysin, a naturally occurring flavonoid, within the context of AD pathology. The intricate mechanisms of action underlying the chrysin‐loaded NLCs are elucidated, shedding light on their potential to modulate key pathways implicated in AD progression. This study advances our understanding of tailored drug delivery systems, specifically highlighting the therapeutic promise of chrysin‐loaded NLCs for the nuanced management of Alzheimer’s Disease.MethodTo overcome these challenges, a Nanostructured lipid carrier (NLC) for Chrysin was devised, employing quality by design (QbD) based Box‐Behnken design (BBD). NLC offers numerous advantages, encompassing increased drug loading, facile preparation, exceptional stability, as well as enhanced bioavailability and permeability across the blood‐brain barrier.ResultThe optimized Chrysin‐loaded NLC formulation exhibited Particle Size, PDI, zeta potential, and drug loading as 66.45nm, 0.19, ‐22mV, and 98% respectively. The formulation was found to be stable after six months in accelerated stability studies. The formulation underwent various pharmacodynamic studies. Pharmacodynamic studies assessed cognitive and motor functions in rats, revealing significant improvements in cognition with both low and high doses respectively. Additionally, the biochemical investigations revealed that the Chrysin‐loaded NLCs effectively decreased the levels AChE enzyme, amyloid β, oxidative stress, and neuroinflammation.ConclusionThis study explores Chrysin‐loaded NLCs as a solution for challenges in Alzheimer’s Disease (AD) treatment. The optimized formulation overcomes Chrysin’s solubility issues, demonstrating improved bioavailability and permeability. Chrysin‐loaded NLCs hold promise as a neuroprotective for AD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/186344